Major findings
The main findings of our study are: (1) procedures to restore or maintain SR, including external cardioversion or ablation, in this population, are rarely performed (only 4% of our population), with no major complication observed whatever the periprocedural antithrombotic protocol was. (2) the vast majority of patients undergoing percutaneous LAA closure will have the same AF status before and one year after the index procedure.
AF evolution disease and LAA arrhythmogenicity
AF is commonly attributed to a trigger represented by pulmonary veins (PV) ectopies [
17]. This location is particularly implicated in paroxysmal AF pathophysiology. In addition, atrial substrate abnormalities underlie AF maintenance. This substrate is usually located around PVs at the beginning of the disease but over time, the atrial substrate invades the left atrium and to a lesser extent the right atrium. This progression of the disease can be due to AF itself or other cardiac uncontrolled risk factors such as obesity, hypertension or diabetes and lead clinically to persistent or permanent AF. Atrial electrical foci location responsible for AF is a matter of debate as no clear consensus for their detection is available at the moment. LAA, even if rarely associated with AF trigger [
18], have been identified in other previous studies, as a potential important origin for AF maintenance during persistent AF. Di Biase et al. [
10] first, reported the potential arrythmogenic role of the LAA during AF. In this study, including 987 patients, LAA firing was observed in 27% of patients and was the only source of AF in 8.7% of this population. Other studies have also highlighted the role of LAA in AF maintenance. Notably, Lim et al. [
19] demonstrated, using a 252-electrode vest for body surface mapping, that LAA could be a focal driver for persistent AF in 50–55% of cases.
Considering these reports, the LAA has been targeted during AF ablation. Di Biase et al. [
20] demonstrated that LAA electrical isolation was associated with better outcomes for patients undergoing persistent AF ablation. Finally, a recent meta-analysis by Friedman et al. confirmed on 7 studies that LAA electrical isolation was associated with lower AF recurrences following AF ablation [
21].
More recently, the potential arrhythmogenic effect of LAA closure on AF disease has come into question. Specifically, the LARIAT system, consisting in epicardial snared LAA occlusion (resulting in LAA ischemia) proved to increase significantly freedom from AF off antiarrhythmic drugs at 12 months follow-up (65% vs 39%) [
12]. However, the arrhythmic effect of endocardial devices such as the Watchman or ACP/Amulet devices is unclear. Indeed, in contrary to surgical LAA snaring, percutaneous LAA closure could not alter the neuroendocrinal function of LAA. We have shown that, in our cohort of 331 patients undergoing endocardial LAA closure, 87% of those with SR at baseline were in SR at one-year follow-up. In addition, 93% of patients with AF at the time of LAA device implantation were still in AF during long term follow-up.
Numerous studies have evaluated the progression of AF disease over time. It has been conceptually established that AF disease progresses steadily from atrial ectopices to paroxysmal AF, persistent AF and finally permanent AF. The CARAF study evaluated 757 patients with paroxysmal AF and demonstrated that at one year follow-up, 8.6% of patients had developed chronic AF and 24.7% at 5 years. Age, significant aortic stenosis or mitral regurgitation, left atrial enlargement and underlying cardiomyopathy were independently associated with the evolution towards chronic AF [
22]. More recently, De Vos et al. studied 1219 patients diagnosed with paroxysmal AF. After one year, 15% of these patients experienced AF disease progression [
23].
Our results are consistent with the natural history of AF disease progression and suggest a neutral arrhythmogenic effect of endocardial LAA closure devices.
AF management for patients with LAA occlusion
Sinus rhythm restoration is a cornerstone of AF therapy [
14]. This can be achieved either using pharmacological or electrical cardioversion, or performing AF catheter ablation.
In Europe, percutaneous LAA closure is predominantly indicated for patients contraindicated to oral anticoagulation [
14]. The FLAAC registry [
15] evaluated prospectively the efficacy and safety on French patients undergoing percutaneous LAA closure from 2013 to 2015. Interestingly, the mean age of this population was 75 years and the mean CHA
2DS
2-VASc score was 4.5 indicating a population with numerous comorbidities. AF rate control strategies are usually preferred in this population rather than rhythm control strategies. This is consistent with the low rate of SR restoration attempts observed in our study (only 4% of the studied population), probably due to the potential complications related to electrophysiogical procedures in this frail population.
LAA closure has been proposed by some authors as a potential alternative to oral anticoagulation in patients without contraindication to OAC. In this specific population, rhythm control achieved with cardioversion or AF ablation is a common management strategy. Of note, patients undergoing rhythm control strategy in our population had a lower CHA2DS2-VASc (2.9 ± 0.4 vs. 4.6 ± 0.1, p < 0.001) and HAS-BLED scores (2.3 ± 0.3 vs. 3.2 ± 0.1, p < 0.01) than the general population included in the registry.
Moreover, as AF ablation requires LA catheterization, it has been proposed in small sample size studies to combine AF ablation and LAA closure [
24,
25]. Gadiyaram et al. recently found that the Watchman or Lariat procedure for patients with electrical LAA isolation during AF ablation was safe and oral anticoagulation could be avoided in 98% of this population [
26]. Li et al. [
27] evaluated 25 patients undergoing combined AF ablation and LAA closure. In 24 patients, oral anticoagulant agents could be stopped at 6 months follow-up. All these studies include small sample sizes and larger series are required to support the efficacy and safety of this combined procedure.
Data evaluating the follow-up of patients with LAA closure undergoing subsequent cardioversion or AF ablation are sparse.
In our population, 7 patients underwent AF ablation. Five of these interventions were combined with LAA closure and two were performed 5 and 7 months after the index procedure, respectively. In addition, as shown in Table
4, one patient had no anticoagulation post-AF ablation without any thromboembolic event after the procedure.
Table 4
Rhythm control intervention during the follow-up period after LAA closure
70′s–80′s | Sinus rhythm | No | No | 2 | Electrical cardioversion | No | VKA | VKA |
80′s–90′s | Atrial fibrillation | Yes | No | 5 | Electrical cardioversion | No | Short term anticoagulation + Antiplatelet therapy | Low Molecular Weight Heparine + Antiplatelet therapy |
80′s–90′s | Sinus rhythm | No | No | 2 | Overdrive pacing | No | Antiplatelet therapy | Antiplatelet therapy |
70′s–80′s | Sinus rhythm | No | No | 4 | Overdrive pacing | No | None | None |
70′s–80′s | Sinus rhythm | No | Yes | 2 | Atrial fibrillation ablation (CP with LAAC, Pulmonary vein isolation) | No | None | DOAC |
60′s–70′s | Sinus rhythm | Yes | Yes | 5 | Left Atrial flutter ablation (Pulmonary vein isolation) | No | Antiplatelet therapy | Antiplatelet therapy |
60′s–70′s | Atrial fibrillation | Yes | No | 2 | Right common flutter ablation (cavotricuspid isthmus ablation) | No | Antiplatelet therapy | Antiplatelet therapy |
70′s–80′s | Sinus rhythm | No | No | 4 | 2 ablation procedures: 1) CP with LAAC (cavotricuspid isthmus ablation); 2) Subsequent ablation: (Pulmonary vein isolation) | No | None VKA | Antiplatelet therapy None |
50′s–60′s | Atrial fibrillation | Yes | No | 3 | Atrial fibrillation ablation (pulmonary vein isolation isolation) and right common flutter ablation (cavotricuspid isthmus ablation) | No | DOAC + Antiplatelet therapy | DOAC + Antiplatelet therapy |
60′s–70′s | Sinus rhythm | Yes | Yes | 4 | Atrial fibrillation ablation (CP with LAAC, Pulmonary vein isolation) | No | DOAC | DOAC |
60′s–70′s | Sinus rhythm | No | No | 1 | Atrial fibrillation ablation (CP with LAAC, Pulmonary vein isolation) | No | Antiplatelet therapy | Low Molecular Weight Heparine + Antiplatelet therapy |
60′s–70′s | Sinus rhythm | No | No | 2 | Atrial fibrillation ablation (CP with LAAC, Pulmonary vein isolation) | No | Antiplatelet therapy + VKA | Antiplatelet therapy + VKA |
60′s–70′s | Sinus rhythm | No | Yes | 2 | Atrial fibrillation ablation (CP with LAAC, Pulmonary vein isolation) | No | None | Low Molecular Weight Heparine + Antiplatelet therapy |
Electrical cardioversion can also be used to restore SR in persistent AF patients. This procedure is systematically followed by a minimum of 1 month of anticoagulation [
14] but in some patients experiencing LAA closure, oral anticoagulants are strictly contraindicated and the need for cardioversion can occur in patients with LAA closure without anticoagulation. Electrical cardioversion following LAA closure have been described in some cohorts of patients. However, the anticoagulation protocol following cardioversion was not clearly described. In our prospective cohort, 4 patients experienced electrical cardioversion or overdrive pacing to restore SR. One patient had no anticoagulation before and after atrial arrhythmia reduction and had no thromboembolic event during the follow-up.
Cullen et al. [
28] described 93 patients undergoing cardioversion after surgical LAA closure. They found a substantial number of patients (37%) with incomplete LAA closure and LA thrombus (28%) assessed on TEE, highlighting the need to exclude left atrial cavity thrombus before cardioversion in patients with LAA closure.
Limitations
This study has several limitations. First, we included only patients with successful LAA closure and there was no control group. The AF recurrence rate after LAA closure was therefore compared to data reported in the literature. However, we believe that this indirect comparison provides interesting findings on the effect of LAA closure on cardiac rhythm. Secondly, most of the patients were old with a high rate of comorbidities and were mainly in persistent/permanent AF at baseline explaining that only of few of them underwent procedure to restore SR. Also this strategy could vary, depending on patient characteristics, individual preference or regional practices. Some of these cardioversions or ablation procedures were performed several months after LAA closure and the follow-up reported in this study for these patients was therefore limited. Our results on the safety of these procedures after LAA closure should therefore be taken with caution. Finally, AF status was only assessed according to ECG performed at baseline and at 1 year follow-up. Even if changes in AF burden assessed for instance by 24 h Holter-ECG, may be a more powerful outcome, our population represents a “real world” cohort of patients and we think that ECG modification between baseline and 1 year follow-up still represent an acceptable way to evaluate AF status modification.